254 related articles for article (PubMed ID: 14533126)
1. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
Aarsland D; Hutchinson M; Larsen JP
Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
[TBL] [Abstract][Full Text] [Related]
2. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Minett TS; Thomas A; Wilkinson LM; Daniel SL; Sanders J; Richardson J; Littlewood E; Myint P; Newby J; McKeith IG
Int J Geriatr Psychiatry; 2003 Nov; 18(11):988-93. PubMed ID: 14618549
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG
Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle.
Pakrasi S; Mukaetova-Ladinska EB; McKeith IG; O'Brien JT
Int J Geriatr Psychiatry; 2003 Oct; 18(10):879-86. PubMed ID: 14533120
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)].
Litvinenko IV; Odinak MM; Mogil'naia VI; Emelin AIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):25-33. PubMed ID: 18427456
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Edwards K; Royall D; Hershey L; Lichter D; Hake A; Farlow M; Pasquier F; Johnson S
Dement Geriatr Cogn Disord; 2007; 23(6):401-5. PubMed ID: 17409748
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Leroi I; Brandt J; Reich SG; Lyketsos CG; Grill S; Thompson R; Marsh L
Int J Geriatr Psychiatry; 2004 Jan; 19(1):1-8. PubMed ID: 14716693
[TBL] [Abstract][Full Text] [Related]
8. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
9. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
10. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients.
Grossi D; Trojano L; Pellecchia MT; Amboni M; Fragassi NA; Barone P
Int J Geriatr Psychiatry; 2005 Jul; 20(7):668-73. PubMed ID: 16021658
[TBL] [Abstract][Full Text] [Related]
11. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).
Litvinenko IV; Odinak MM; Mogil'naya VI; Emelin AY
Neurosci Behav Physiol; 2008 Nov; 38(9):937-45. PubMed ID: 18975103
[TBL] [Abstract][Full Text] [Related]
13. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Freund-Levi Y; Jedenius E; Tysen-Bäckström AC; Lärksäter M; Wahlund LO; Eriksdotter M
Am J Geriatr Psychiatry; 2014 Apr; 22(4):341-8. PubMed ID: 24035407
[TBL] [Abstract][Full Text] [Related]
14. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
15. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
16. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
[TBL] [Abstract][Full Text] [Related]
17. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
18. [Galantamine therapy in dementia associated with CADASIL].
Posada IJ; Ferrero M; Lopez-Valdes E; Goni-Imizcoz M
Rev Neurol; 2008 Sep 16-30; 47(6):299-300. PubMed ID: 18803156
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of galantamine in dementia: a series of case reports.
Dale MC; Libretto SE; Patterson C; Anderson J; Choudhury T; McCafferty F; McWilliam C; Richardson M
Curr Med Res Opin; 2003; 19(6):508-18. PubMed ID: 14594523
[TBL] [Abstract][Full Text] [Related]
20. Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
Ishikawa K; Motoi Y; Mizuno Y; Kubo S; Hattori N
Psychogeriatrics; 2014 Jun; 14(2):93-100. PubMed ID: 24661498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
